No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
RNAZ Transcode Therapeutics
- 0.502
- +0.001+0.10%
Close Apr 18 16:00 ET
- 0.478
- -0.024-4.78%
Post 18:32 ET
2.92MMarket Cap-4P/E (TTM)
0.520High0.475Low406.09KVolume0.509Open0.502Pre Close191.74KTurnover7.00%Turnover RatioLossP/E (Static)5.81MShares356.00052wk High1.77P/B2.91MFloat Cap0.47052wk Low--Dividend TTM5.81MShs Float5600.000Historical High--Div YieldTTM8.97%Amplitude0.470Historical Low0.472Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
TransCode Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/16/2024 536.81% HC Wainwright & Co. → $3 Reiterates Buy → Buy 04/03/2024 536.81% HC Wainwright & Co. →
TransCode Therapeutics: A Promising Oncology Investment With FDA-Backed Clinical Advancements
Express News | Transcode Therapeutics Announces FDA Clearance to Initiate Phase 1/2 Clinical Trial With Ttx-Mc138 in Patients With Advanced Solid Tumors
Promising Phase 0 Results and Upcoming Trial Boost Confidence in TransCode Therapeutics
Express News | HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $3 Price Target
TransCode Therapeutics Reports FY Results
Comments
Therapeutics Company Secures FDA Clearance For Solid Tumor Clinical Trial
The Dawn of a New Era in Cancer Treatment: FDA Greenlights TransCode Therapeutics' Revolutionary Trial.
In a significant leap towards transforming cancer care, TransCode Therapeutics, Inc., a beacon of innovation in the oncology sphere, has received the much-anticipated nod from the U.S. Food and Drug Administration (FDA) to initiate a groundbreaking Phase 1/2 clinical trial. This trial is set to explore the potential of T...
In a significant leap towards transforming cancer care, TransCode Therapeutics, Inc., a beacon of innovation in the oncology sphere, has received the much-anticipated nod from the U.S. Food and Drug Administration (FDA) to initiate a groundbreaking Phase 1/2 clinical trial. This trial is set to explore the potential of T...
$Transcode Therapeutics(RNAZ.US$ Transcode Therapeutics Announces FDA Clearance to Initiate Phase 1/2 Clinical Trial With Ttx-Mc138 in Patients With Advanced Solid Tumors
2
Percentage of shares sold short:
$Aclarion(ACON.US$ 0.76%
$SenesTech(SNES.US$ 7.6%
$Transcode Therapeutics(RNAZ.US$ 71.11%
$Revelation Biosciences(REVB.US$ 9.24%
$Panbela Therapeutics(PBLA.US$ 2.21%
$Aclarion(ACON.US$ 0.76%
$SenesTech(SNES.US$ 7.6%
$Transcode Therapeutics(RNAZ.US$ 71.11%
$Revelation Biosciences(REVB.US$ 9.24%
$Panbela Therapeutics(PBLA.US$ 2.21%
1
2
😳
$Opko Health(OPK.US$ CEO and Co-founder Mr Frost bought 1 million shares 1 week before earnings out. Keep a watch on this.. Fishy!
Below are some stocks on my watchlist.
$Semilux(SELX.US$
$WiSA Technologies(WISA.US$
$Aesthetic Medical International(AIH.US$
$Inspire Veterinary Partners(IVP.US$
$Transcode Therapeutics(RNAZ.US$
$Biodexa Pharmaceuticals(BDRX.US$
$HUB Cyber Security(HUBC.US$
$Tian Ruixiang(TIRX.US$
$Inpixon(INPX.US$
$Treasure Global(TGL.US$
$Golden Heaven(GDHG.US$
$Next.e.GO(EGOX.US$
...
Below are some stocks on my watchlist.
$Semilux(SELX.US$
$WiSA Technologies(WISA.US$
$Aesthetic Medical International(AIH.US$
$Inspire Veterinary Partners(IVP.US$
$Transcode Therapeutics(RNAZ.US$
$Biodexa Pharmaceuticals(BDRX.US$
$HUB Cyber Security(HUBC.US$
$Tian Ruixiang(TIRX.US$
$Inpixon(INPX.US$
$Treasure Global(TGL.US$
$Golden Heaven(GDHG.US$
$Next.e.GO(EGOX.US$
...
2
3
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg